
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc. is currently perceived to have an attractive valuation, as evidenced by recent increases in price targets that suggest substantial potential for growth from its current share price. The company is advancing its lead product, stenoparib, which has demonstrated promising clinical outcomes, including a median overall survival surpassing 25 months for patients enrolled in its Phase 2 trial, highlighting its potential in addressing critical treatment gaps. This positive outlook is further supported by the company's innovative use of its Drug Response Predictor (DRP) technology to optimize patient selection, ultimately enhancing clinical efficacy and outcomes for patients with advanced recurrent ovarian cancer.
Bears say
Allarity Therapeutics is experiencing significant financial instability, highlighted by a net loss of $2.8 million, resulting in an earnings per share (EPS) of $(0.19), which slightly missed estimates of $(0.23). The company's ongoing financial losses raise concerns about balance sheet and liquidity risks, especially amid the inherent uncertainties of clinical trials and the potential failure to achieve regulatory approvals for its lead asset, stenoparib. Additionally, external factors such as market competition and shifting investor sentiment towards biotech stocks further exacerbate the challenges facing Allarity Therapeutics, contributing to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares